Ironwood Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 2/6
Ironwood Pharmaceuticals has a total shareholder equity of $-311.3M and total debt of $598.8M, which brings its debt-to-equity ratio to -192.3%. Its total assets and total liabilities are $389.5M and $700.9M respectively. Ironwood Pharmaceuticals's EBIT is $95.4M making its interest coverage ratio 3.4. It has cash and short-term investments of $88.2M.
Key information
-192.3%
Debt to equity ratio
US$598.82m
Debt
| Interest coverage ratio | 3.4x |
| Cash | US$88.21m |
| Equity | -US$311.33m |
| Total liabilities | US$700.85m |
| Total assets | US$389.52m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: I76 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: I76 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: I76 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: I76's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable I76 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: I76 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 29.5% per year.